Skip to main content

Jiangsu Recbio Technology Co., Ltd. (2179.HK)

Hong Kong Stock Exchange Healthcare BiotechnologyView data quality →
30.0Poor

ValueMarkers Composite Index

Top 0%#44,630 of 44,707

DCF data not available

Piotroski
2/9
Weak
Beneish
-3.11
Low Risk
Altman
0.01
Distress
DCF Value
-
N/A
ROIC
-39.8%
Low
P/E
-
Unlock Full Analysis · Free Trial
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Jiangsu Recbio Technology Co., Ltd. (2179.HK) — VMCI valuation read

Jiangsu Recbio Technology Co., Ltd. (2179.HK) carries a VMCI composite of 30/100, 20 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 2179.HK in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 2179.HK insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 2179.HK trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.2x leaves covenant headroom, the line to track on Jiangsu Recbio Technology Co., Ltd.'s next 10-Q.

2179.HK fell 2.5% over the trailing 7 days, with a -11.4% read on a 30-day basis.

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.

CEO: Yong Liu531 employeesCNwww.recbio.cn

Related Stocks in Healthcare

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Healthcare StocksStock ScreenerTop Rated StocksFinancial GlossaryDCF CalculatorValue Investing Academy2179.HK Dividend ProfileCompare 2179.HKETFs holding 2179.HKGlobal Markets

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 2179.HK’s VM Score.

P/E Ratio (TTM)EV/EBITDAFCF YieldReturn on Invested Capital (ROIC)Piotroski F-ScoreAltman Z-ScoreBeneish M-ScoreMargin of SafetyDCF Intrinsic ValueGraham NumberROIC-WACC SpreadWACC

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.